CLAREMONT, Calif.--(BUSINESS WIRE)--Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced that it has been awarded a $2.2 million ...
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases ...
High-flow nasal oxygen therapy showed no benefit after cardiac surgery in a major trial. Learn more about the study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results